Navigation Links
TCT 2010 to have significant impact on interventional cardiology practices and patient care
Date:4/13/2010

NEW YORK, NY -- APRIL 13, 2010 TCT 2010 (Transcatheter Cardiovascular Therapeutics) will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

The important role of interventional cardiology has figured prominently in recent current events with the announcement that former President Clinton received a heart stent in February at New York-Presbyterian Hospital, followed by the reporting of clinical trial data showing promising results for a heart valve repair device that is inserted via a catheter.

At TCT 2010 (September 21-25 in Washington, DC), late breaking data from clinical trials on the next generation of stents, valve repair and replacement, and the interactions and effectiveness of new medicines will shed light on the best ways to treat patients.

"Catheter-based valve repair and replacement, novel stents, and the effectiveness of various drugs used to treat heart disease are going to be among the major topics at TCT this year," said Gregg W. Stone, MD, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation. TCT is organized by the Cardiovascular Research Foundation.

"Non-surgical aortic valve replacement has the potential to be life saving for people who are at high risk for open heart surgery," Stone said. "As the population ages, this technique may dramatically benefit the quality of life for patients whose aortic valves (the valve through which blood passes from the heart to the rest of the body) fail to function properly. We are hopeful that new trial data that will be presented at TCT will usher in the field of non-operative aor
'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Sunquest Announces Significant Speaker Schedule for HIMSS 2010
2. Announcing New Book 'Ultimate Procrastination Cure', with a Significantly Different Approach to Stop Procrastinating
3. Mortality rates for pediatric rheumatology patients significantly lower than previously reported
4. Digital mammography delivers significantly less radiation than conventional mammography
5. Counterfeit Internet drugs pose significant risks and discourage vital health checks
6. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
7. Study finds significantly worse outcomes in cancer patients with cognitive impairment
8. New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums
9. MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure
10. Add Drama and Lift Spirits While Significantly Reducing Energy Cost; Peachtree Introduces the Evolution Series, LED, Energy Efficient Wall Sconce
11. Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 The North America ... in North America with analysis and forecast of revenue. ... grow from around $273.1 million in 2013 to $490.1 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:7/14/2014)... Employers looking to lower their ... more benefit options must understand how purchasing benefits ... are the future of employee benefits. , Horizon ... BCBSNJ) is offering a free webinar, The Future ... Options, to demonstrate how HorizonSelect, its private online ...
(Date:7/14/2014)... Continuing a steady trend of growth in the ... of first-quarter success with Orange Regional Medical Center, Nexus ... by CEO and President Dr. Virginia Feldman – has ... members. Robert Poltenovage has joined the Nexus ... LPN and Angelica D’Amico have joined the Nexus Health ...
(Date:7/14/2014)... The European Lecithin Market report explains ... and projection of revenue. The Lecithin Market in Europe ... 2012 to $315.9 million by 2019, at a CAGR ... the TOC of the European Lecithin Market report, to ... also provides a glimpse of the segmentation in the ...
(Date:7/14/2014)... use of antibiotics is still prevalent among terminal patients ... despite little evidence that the medications improve symptoms or ... effects. , The use of antibiotics is so engrained ... discharged from hospitals directly to a hospice program leave ... one fourth of them don,t have a documented infection ...
Breaking Medicine News(10 mins):Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 3Health News:Antibiotic use prevalent in hospice patients despite limited evidence of its value 2
... , TAMPA, Fla. , Jan. ... the United States Preventative Task Force (USPTF), the Obesity Action ... add health insurance coverage of the recommended childhood obesity treatments. ... treating childhood obesity in moderate to intensive programs helps children ...
... , MORRISTOWN, N.J. , Jan. 19 ... a leading specialty pharmaceutical company, today confirmed that its subsidiary, ... (ANDA) with the U.S. Food and Drug Administration (FDA) seeking ... the expiration of U.S. Patent No. 5,827,529.  Watson,s lidocaine topical ...
... , Berk Prepares to Return as CEO , ... President Joel Seligman today announced that on March 1 ... full-time CEO of the Medical Center while Mark B. Taubman ... of Rochester School of Medicine and Dentistry .   , "I am excited ...
... will be held in Barcelona, Spain (Centre Convencions Internacional ... 24 - Saturday 27 March 2010. The ... the only one that involves all the major players ... between clinicians, scientists and patients in a partnership of ...
... survivors wait up to five years before disclosing they were ... Montral, the Universit du Qubec Montral and the Universit ... . "The number of victims who never reveal their ... very high," says co-author Mireille Cyr, a psychology professor of ...
... closely supported by a nurse-physician primary care team are twice ... those who receive usual care, according to a study by ... The research, published online in the latest edition of the ... 18 months of a randomized controlled trial, Guided Care recipients ...
Cached Medicine News:Health News:Obesity Action Coalition Calls on Insurers and Employers to Increase Access to Childhood Obesity Treatments Based on Recent United States Preventative Task Force Recommendations 2Health News:Watson Confirms Filing of FDA Application for Generic Lidoderm(R) 2Health News:Watson Confirms Filing of FDA Application for Generic Lidoderm(R) 3Health News:New Dean of School of Medicine and Dentistry Announced 2Health News:New Dean of School of Medicine and Dentistry Announced 3Health News:Disclosing sexual abuse is critical 2Health News:Guided Care participants rate quality of health care high 2
(Date:7/14/2014)... A new Manhattan Research study, ... finds that members of pharmacy and therapeutics ... and pharmacy benefits managers (PBMs) are shifting the ... of formulary decision makers report that they are ... decision making process today than a year ago. ...
(Date:7/14/2014)...  Clinicians at a leading cancer center in ... first in the country to commence advanced lung, ... Clinac® medical linear accelerator from Varian Medical Systems ... High Intensity Mode dose delivery capability, which is ... treatment times and deliver stereotactic body radiotherapy and ...
(Date:7/14/2014)... 14, 2014  Patients and patient advocates are rallying ... and other major pharmacy benefit managers (PBMs) begin unprecedented ... impact millions of patients who rely on compounded medicines ... pain from cancer, diabetes and other illnesses. Express Scripts ... on July 15. In a matter of ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... SOUTHAMPTON, England, June 29 Vantia ... drugs,targeting large, underserved medical markets, announces positive results ... development compound VA106483 for,nocturia. The trial showed that ... sustained anti-diuretic effect in patients, as determined by,increased ...
... England and TOKYO, June 29 , ... Sosei Group Corporation ("Sosei"; TSE Mothers ... commencement of a Phase III,clinical study by Novartis, with NVA237, ... obstructive pulmonary disease,(COPD). NVA237 is a dry powder formulation for ...
Cached Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4
Disposable Feather Blades, 50 per pack...
Knife sharpening back for Standard Knife, C Profile...
... The Cryostage freezing stage is a refrigerated design ... holder, primarily for use with the 8000 sledge ... sledge microtomes. ,The refrigerated stage gives a large ... surface is ridged to provide good adhesion between ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
Medicine Products: